CClinicalTrials.gg
CompletedNCT00891189Updated Sep 23, 2016

Determine the Relationship Between Circadian Rhythms and Nocturnal Asthma

An observational study in Asthma, sponsored by Northwestern University. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-23.

Sponsored by Northwestern University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Asthma is a disease that affects the lungs. Symptoms include repeated episodes of wheezing, breathlessness, chest tightness, and nighttime or early morning coughing. Some people with asthma experience worse symptoms at night, which is known as nocturnal asthma (NA). The reason for the decline in lung function at night in some asthmatics is not well understood, but it may be linked to the human biological clock, which controls daily activity and sleep rhythms. To determine whether differences in biological clocks relate to worsening nocturnal lung function, this study will evaluate the circadian rhythms of people with NA, people with non-nocturnal asthma, and healthy people.

Read the detailed description

Nocturnal worsening of asthma, frequently called NA, is a common problem among some people with asthma and one that leads to increased morbidity and mortality. It is still unknown why lung function worsens at night in some asthmatics and not others. There is a possible relationship between NA, biological clocks, and circadian rhythms, but more research is needed to understand this relationship. Although the diurnal nature of NA has been shown repeatedly in studies, circadian rhythms have not yet been implicated as a related factor. This study will examine the pathophysiology of NA as it relates to circadian biology and will specifically explore physiological and molecular aspects.

This study will include people with asthma, people with NA, and healthy people. Potential participants will attend a screening visit to assess general health and severity of asthma, if present. They will also complete 2 weeks of diary recordings of their daily symptoms and airway function.

Eligible participants will then attend two study visits. The first study visit will last 1 hour and may include a methacholine challenge and bronchodilator testing, both of which will measure lung function. For 2 weeks before the second study visit, participants will keep records of their sleep patterns. The second study visit will be a hospital stay that will last for 2.5 days. While in the hospital, participants will undergo periodic blood draws and lung function testing. During waking hours, participants will remain quietly awake. During the first night, participants will be monitored while they sleep. During the second night, participants will stay awake for 28 hours, which will continue into the third day. Then, on the third day, participants will sleep for 8 hours while again being monitored. Upon waking, participants will be given a regular meal and discharged.

02

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Circadian Rhythm
03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's enrollment of 20 is below the median of 150 across 970 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Northwestern University is the lead sponsor of 1,398 studies on the registry; 201 are open to participants now.

Of its 102 completed or terminated interventional studies of FDA-regulated products, 73 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy and asthmatic participants

Eligibility criteria

Inclusion Criteria for People with Asthma:

  • A physician diagnosis of asthma, consistent clinical history, and either 1) airway hyperresponsiveness indicated by a 20% or greater decrease in forced expiratory volume at one second (FEV1) in response to inhalation of methacholine at 8 mg/mL or less, or 2) bronchodilator-responsive expiratory airflow limitation (if FEV1 less than 70% of predicted value or less than 1.5 L, improving at least 200 mL and 12% in response to 180 μg of albuterol aerosol). Patients with NA should meet the above criteria and demonstrate an overnight decrease in peak flow of 20% or greater on at least four of seven nights at home.

Inclusion Criteria for all Participants:

  • Able to follow directions

Exclusion Criteria for Participants with Asthma:

  • Use of oral steroids within 2 weeks of study entry
  • Use of cromolyn, leukotriene antagonist, or theophylline within 1 week of study entry
  • History of cognitive or other neurological disorder
  • Active symptoms of Diagnostic and Statistical Manual IV (DSM-IV) criteria for any major psychiatric disorder, alcohol abuse, or substance abuse
  • History of, or concurrent, unstable or serious medical illness
  • Shift work
  • History or evidence of chronic obstructive pulmonary disease (COPD)
  • Tobacco smoking within the last month, or history of smoking greater than 5 pack-years
  • Pregnancy or the desire to become pregnant during the study period
  • Hematocrit less than 30
  • Worsening or unstable asthma that requires use of a bronchodilator for more than four times a day

Exclusion Criteria for all Participants:

  • History of obstructive sleep apnea or a body mass index more than 36, or other sleep disorder as assessed by questioning or polysomnography (PSG)
  • History of cognitive or other neurological disorder
  • Currently meets DSM-IV criteria for any major psychiatric disorder, alcohol abuse, or substance abuse (as assessed by an interview)
  • Concurrent unstable or serious medical illness (other than asthma)
  • Current use of psychoactive medications, including antidepressants, anxiolytics, neuroleptics, anticonvulsants, hypnotics, and stimulant medications
  • Shift work
  • A daily caffeine intake greater than 4 cups per day
  • Smoking
  • Pregnancy or the desire to become pregnant during the study period
  • Atrial fibrillation or paced heart rhythm
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
20 participants (actual)

Groups and cohorts

  • 1 Control

    Healthy participants without asthma

  • 2 Non-nocturnal asthma

    Participants with non-nocturnal asthma

  • 3 Nocturnal asthma

    Participants with nocturnal asthma

06

What researchers measure

Primary outcomes

  1. Spirometry

    Time frame: Measured during the 28-hour constant routine testing

Secondary outcomes

  1. Cortisol, melatonin, exhaled nitric oxide, inflammatory cytokine levels, clock gene expression, and heart rate variability

    Time frame: Measured during the 28-hour constant routine testing

07

Study locations

1 site
  • Northwestern University
    Chicago, Illinois 60611, United States
08

References and documents

Publications

  • Sutherland ER. Nocturnal asthma. J Allergy Clin Immunol. 2005 Dec;116(6):1179-86; quiz 1187. doi: 10.1016/j.jaci.2005.09.028. Epub 2005 Nov 8. PubMed 16337443 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00891189
Lead sponsor
Northwestern University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Phyllis Zee (Professor, Northwestern University) — Principal investigator
First posted
May 1, 2009
Start date
Jan 2009
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Sep 23, 2016

Study contacts

Brandon S. Lu, MD, MS
principal investigator · Northwestern University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion